Investors wait Cerecor Inc. (NASDAQ:CERC)’s quarterly earnings on April, 1., according to Faxor. Analysts have expectation on stock’s earnings per share of $-0.10. That’s up 9.09 % from last year’s $-0.11 earnings per share. -61.54 % EPS growth is what Wall Street’s forecasts after $-0.26 reported EPS previous quarter. The stock decreased 5.57% or $0.33 during the last trading session, touching $5.59.Cerecor Inc. has volume of 54,769 shares. Since March 25, 2018 CERC has risen 54.52% and is uptrending. CERC outperformed by 50.15% the S&P500.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders.The company has $238.43 million market cap. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder , as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD.Last it reported negative earnings. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy.

For more Cerecor Inc. (NASDAQ:CERC) news posted briefly go to: Globenewswire.com, Benzinga.com, Benzinga.com, Benzinga.com or Seekingalpha.com. The titles are as follows: “Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results – GlobeNewswire” posted on February 28, 2019, “72 Biggest Movers From Yesterday – Benzinga” on February 27, 2019, “71 Biggest Movers From Yesterday – Benzinga” with a publish date: March 06, 2019, “81 Biggest Movers From Friday – Benzinga” and the last “FDA accepts Cerecor’s IND for CERC-801 – Seeking Alpha” with publication date: January 22, 2019.